2 active not recruiting, 1 recruiting, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow PI3K Gene Mutation: new trials by email Literature Review of PI3K Gene Mutation trials Research Report on PI3K Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer OKI-219, Fulvestrant, Trastuzumab - Advanced Cancer, Breast Cancer | Phase 1 | Active not recruiting | OnKure, Inc. | 200 | 2024-02-26 | 2026-07-06 |
| Bile Acids in Acute Insulin Resistance Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor - PI3K Gene Mutation, AKT Gene Mutation | Terminated | Columbia University | 3 | 2022-06-10 | 2025-01-16 | |
| Genetic Testing in Guiding Treatment for Patients With Brain Metastases Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib - CDK Gene Mutation, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 50 | 2019-10-17 | 2026-10-30 |
Arteriovenous Malformations (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Cardiovascular Diseases (1) · Dyslipidemias (1) · Insulin Resistance (1) · Lymphangioma (1) · Lymphangioma, Cystic (1) · Lymphatic Abnormalities (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Skin Diseases, Vascular (1) · Vascular Malformations (1)
Neoplasms (3) · Neoplasms by Site (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Brain Diseases (1) · Breast Diseases (1) · Cardiovascular Abnormalities (1) · Cardiovascular Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Glucose Metabolism Disorders (1) · Hemic and Lymphatic Diseases (1) · Hyperinsulinism (1)
Alpelisib (1) · Fulvestrant (1) · Trastuzumab (1) · abemaciclib (1) · adagrasib (1) · entrectinib (1) · mirdametinib (1) · ribociclib (1) · tucatinib (1)
Alliance for Clinical Trials in Oncology (1) · Columbia University (1) · Murdoch Childrens Research Institute (1) · OnKure, Inc. (1)
United States (3) · Australia (1) · Belgium (1) · France (1) · Italy (1) · South Korea (1) · Spain (1)
Lydia Pathmanathan, MBBS, FRACP. (1) · Priscilla Brastianos, MD (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1)
U10CA180821 (1)